Stay updated on Faricimab in Neovascular AMD Clinical Trial
Sign up to get notified when there's something new on the Faricimab in Neovascular AMD Clinical Trial page.

Latest updates to the Faricimab in Neovascular AMD Clinical Trial page
- Check4 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check25 days agoChange Detected- Added Publication citation: Pitcher JD 3rd, Koh AHC, Tan CS, Vakharia P, Dagincourt N, Patel S, Yang M, Margaron P, Gallego-Pinazo R. Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2026 Feb 19:e256365. Online ahead of print.SummaryDifference0.0%

- Check40 days agoChange DetectedMinor internal revision from v3.4.1 to v3.4.2 with no user-facing changes to study content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check47 days agoChange DetectedThe page shows a site revision from v3.4.0 to v3.4.1. No changes to study content, eligibility criteria, or results are visible.SummaryDifference0.0%

- Check55 days agoChange DetectedMinor UI/metadata updates were applied, including enabling the glossary display and updating to revision v3.4.0, with removal of older QC status text and references to No FEAR Act data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Faricimab in Neovascular AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Faricimab in Neovascular AMD Clinical Trial page.